1. Nasser NJ, Fox J, Agbarya A. Potential Mechanisms of Cancer-Related Hypercoagulability. Cancers (Basel). 2020;12(3):566. doi: 10.3390/cancers12030566.
2. Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013;119(3):648-55. doi: 10.1002/cncr.27772.
3. Seng S, Liu Z, Chiu SK, Proverbs-Singh T, Sonpavde G, Choueiri TK, et al. Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol. 2012;30(35):4416-26. doi: 10.1200/JCO.2012.42.4358.
4. Nadeau Nguyen MC, Woronow D, Binks B, Nayernama A, Jones SC. Cisplatin-Associated Aortic Thrombosis: A Review of Cases Reported to the FDA Adverse Event Reporting System. JACC CardioOncol. 2021;3(1):165. doi: 10.1016/j.jaccao.2020.11.017.
5. Sato N, Mishima T, Okubo Y, Okamoto T, Shiraishi S, Tsuchida M. Acute aortic thrombosis in the ascending aorta after cisplatin-based chemotherapy for esophageal cancer: a case report. Surg Case Rep. 2022;8(1):75. doi: 10.1186/s40792-022-01431-8.